News >

PARP Investigations Continue on Path Toward Precision Medicine in Prostate Cancer

Caroline Seymour
Published: Tuesday, Mar 31, 2020

William Oh, MD

William Oh, MD
The use of PARP inhibitors against DNA damage repair (DDR) alterations in prostate cancer is the first display of the potential for widespread precision medicine in the field, according to William K. Oh, MD, in a presentation during the 13th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication